OBJECTIVES: To describe cases of new onset of inflammatory bowel disease (IBD) in
patients with inflammatory rheumatic disease (IRD) receiving anti-TNF-α therapy …

Objective Ankylosing spondylitis (AS) and inflammatory bowel disease (IBD) are clinically
and pathologically linked. Anti–tumor necrosis factor (anti‐TNF) agents are efficacious in …

TNF-α inhibitors (TNFis) have revolutionized the treatment of certain chronic immune-
mediated diseases, being widely and successfully used in rheumatic inflammatory diseases …

Musculoskeletal symptoms (articular, periarticular and muscular involvement, osteoporosis
and related fractures, and fibromyalgia) are the most common frequent extra-intestinal …

Objective: To evaluate the efficacy and tolerability of anti-tumour necrosis factor α (TNFα)
monoclonal antibody (infliximab) in the treatment of spondyloarthropathy (SpA) associated …

The seronegative spondyloarthropathies (SpAs) are associated both with clinical and
subclinical colitis. Recently biological blockade with the tumour necrosis factor alpha (TNFα) …

OBJECTIVES: To report on the clinical evolution of a patient with ankylosing spondylitis (AS)
treated with etanercept who subsequently developed Crohn's disease, to review the …

Background Anti‐TNFα agents have revolutionised management of chronic inflammatory
diseases. Paradoxically, these agents might provoke development of de novo autoimmune …

Anti-TNF antibodies have acquired a prominent place in the management of IBD (including
Crohn's disease and ulcerative colitis), rheumatologic conditions (such as rheumatoid …

Background The incidence of lupus-like reactions (LLRs) in patients with inflammatory
bowel disease (IBD) treated with anti-tumor necrosis factor (ATNF) has not been well …